Please use this identifier to cite or link to this item: https://hdl.handle.net/1822/87308

TitleTaking the competitor's pill: when combination therapies enter pharmaceutical markets
Author(s)Brekke, Kurt R.
Dalen, Dag Morten
Straume, Odd Rune
KeywordsPharmaceutical markets
Combination therapies
Therapeutic competition
Issue date2023
PublisherUniversidade do Minho. Núcleo de Investigação em Políticas Económicas (NIPE)
Abstract(s)We study the competitive effects of combination therapies in pharmaceutical markets, which crucially hinge on the additional therapeutic value of combinatory use of drugs and the therapeutic substitutability with the most relevant monotherapy. With large additional therapeutic value,the introduction of combination therapies leads to higher prices and, somewhat paradoxically, may reduce the health plan´s surplus. Although combination therapies imply that drugs become both substitutes and complements, we show that drug prices increase if the firms are allowed to coordinate their prices. Allowing for price discrimination might increase allocational effciency, but only at the expense of higher purchasing costs.
TypeWorking paper
URIhttps://hdl.handle.net/1822/87308
Publisher versionhttps://nipe.eeg.uminho.pt/publicacoes-nipe/#documentos-de-trabalho
Peer-Reviewedno
AccessOpen access
Appears in Collections:NIPE - Documentos de Trabalho

Files in This Item:
File Description SizeFormat 
WP-12.2023.pdfTaking the competitor´s pill: When combination therapies enter pharmaceutical markets1,19 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID